LGVN

NASDAQ 已收盘

Longeveron

1.66 USD
▼-0.16-8.79%
盘后 2.40 0.00%
2026-11-20
市值
$5.60M
市盈率
—
EPS
-8.12
股息率
—
52 周区间
1.31 – 12.30
成交量
27.26K
Beta
0.91
目标价
61.25
52W 低 1.3152W 高 12.30
价格走势

公司简介

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated...

关联新闻